Mito-TEMPO [1334850-99-5]
Cat# NB-64-09295-5mg
Size : 5mg
Contact local distributor :
Phone : +1 850 650 7790
Remove All
Mito-TEMPO
Copy Product InfoSynonyms:
Catalog No. T19428 Copy Product Info
Purity: 99.22%
Mito-TEMPO, a mitochondria-targeted superoxide dismutase mimetic, scavenges superoxide and alkyl radicals, preventing mitochondrial oxidation, necrosis, and apoptosis.
Cas No. 1334850-99-5
Custom-made molecule. TargetMol’s expert synthesis team delivers cost-effective solutions. Contact us for inquiries. Committed to serving you.
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.22%
Contact us for more batch information
Product Information
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Mito-TEMPO, a mitochondria-targeted superoxide dismutase mimetic, scavenges superoxide and alkyl radicals, preventing mitochondrial oxidation, necrosis, and apoptosis. |
| In vitro | METHODS: Human neuroblastoma cells SH-SY5Y were treated with Mito-TEMPO (25-100 μM) for 24 h. Cell viability was detected using MTT assay. RESULTS: No cytotoxic effect was shown on the cells in the Mito-TEMPO-treated group, and a significant increase in cell viability was detected after Mito-TEMPO treatment. [1] METHODS: Normal rat proximal renal tubular epithelial cell line NRK-52E was pretreated with Mito-TEMPO (10 μM) for 1 h, then stimulated with oxalate (700 μM) for 1 h. The mitochondrial membrane potential was detected by using MMP assay kit (JC-1). RESULTS: The control cells showed bright red fluorescence. Compared with the control, oxalate treatment attenuated the red fluorescence, and these changes were reversed by pretreatment with Mito-TEMPO. The RESULTS suggest that oxalate induces mitochondrial dysfunction, and Mito-TEMPO can inhibit this effect. [2] |
| In vivo | METHODS: To investigate the protective effect against hepatotoxicity, APAP (300 mg/kg) was intraperitoneally injected into C57BL/6J mice, and Mito-TEMPO (20 mg/kg in saline) was injected intraperitoneally 1.5-3 h later. RESULTS: Mito-TEMPO had a protective effect on the late hepatotoxicity of APAP. [3] METHODS: To investigate the effects on coronary vasodilatation and endothelial SK channel activity, Mito-TEMPO (1 mg/kg in saline) was intraperitoneally injected into C57BL/6J mice with or without diabetes once daily for four weeks. RESULTS: After 4 weeks of treatment with Mito-TEMPO, diabetic mice showed significantly improved endothelium-dependent diastolic responses of coronary arteries to ADP or NS309 and endothelial SK channel currents compared to untreated diabetic mice. [4] |
| Molecular Weight | 510.03 |
| Formula | C29H35N2O2P.Cl |
| Cas No. | 1334850-99-5 |
| Smiles | [O]N1C(C)(C)CC(NC(C[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)=O)CC1(C)C.[Cl-] |
| Relative Density. | no data available |
| Storage | Keep away from moisture, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 60 mg/mL (117.64 mM), Sonication is recommended. DMSO: 255 mg/mL (499.97 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (9.8 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||